IP Library › Granted Patent US 12662536
Granted Patent B2
US 12662536 · App. 17/636,440 · Granted Jun 23, 2026

Bispecific antibody targeting CD3 and CD20 and use thereof

Inventors: Yang Yang (Yangpu, CN); Wei Yin (Yangpu, CN)
C07K16/2809A61P35/02C07K16/2887C07K16/468A61K2039/505C07K2317/31C07K2317/55C07K2317/73C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12662536
App. No.
17/636,440
Granted
Jun 23, 2026
Kind
B2
Abstract

The present invention provides an anti-CD3 single chain Fab molecule and an anti-CD20 single chain Fab molecule and their use in preparation of a bispecific antibody. The present invention also provides a bispecific antibody targeting CD3 and CD20 and its use in preparation of a medicament for treatment of a B-cell related disease.

Claims (2)

1 . An anti-CD3 single chain Fab molecule comprising a Fab light chain and a Fab heavy chain, wherein C-terminal of the Fab light chain is connected to N-terminal of the Fab heavy chain by a linking peptide having a length of 60 amino acids and the anti-CD3 single chain Fab molecule comprises an amino acid sequence as set forth in SEQ ID NO: 6 or 9.

2 . An anti-CD20 single chain Fab molecule comprising a Fab light chain and a Fab heavy chain, wherein C-terminal of the Fab light chain is connected to N-terminal of the Fab heavy chain by a linking peptide having a length of 60 amino acids and the anti-CD20 single chain Fab molecule comprises an amino acid sequence as set forth in SEQ ID NO: 10.